{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:54:13Z","timestamp":1790690053025,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) represents the hepatic manifestation of ectopic fat accumulation and adipose tissue dysfunction. Excess visceral adiposity promotes adipose tissue hypoxia, macrophage infiltration, and chronic low-grade systemic inflammation, generating systemic metabolic stress that may extend to the lung through a proposed liver\u2013lung axis (hepatopulmonary crosstalk). This systematic review synthesizes current evidence on the associations between MASLD and major respiratory diseases, with emphasis on shared obesity-driven mechanisms. A systematic review was conducted in accordance with the PRISMA 2020 guidelines and registered in PROSPERO (CRD420261301893). PubMed\/MEDLINE, Embase, Web of Science, and Google Scholar were searched from inception through February 28, 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Twenty-two studies, 21 observational and 1 Mendelian randomization study (MRS) study reported associations between MASLD and several respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea (OSA), interstitial lung disease, pulmonary hypertension, and respiratory mortality. MASLD prevalence was high among patients with COPD and OSA, and was associated with worse respiratory phenotypes, increased exacerbations, and higher respiratory mortality in several cohorts. Liver fibrosis appeared more strongly associated with impaired lung function and adverse outcomes than steatosis alone. MRS were critically re-evaluated, and do not consistently support causal relationships for most respiratory conditions, with the exception of OSA, which showed evidence suggestive of a potential causal association. Shared mechanisms include visceral adiposity, adipokine imbalance, insulin resistance, systemic cytokine activation (IL-6, TNF-\u03b1), endothelial dysfunction, oxidative stress, intermittent hypoxia, and profibrotic transforming growth factor-beta (TGF-\u03b2)\u2013mediated pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current evidence supports a clinically significant association between MASLD and respiratory disease, particularly COPD, OSA and asthma. Recognizing MASLD as a marker of systemic metabolic dysfunction may improve integrated cardiometabolic and pulmonary risk stratification. Prospective and interventional studies targeting weight reduction and metabolic signaling are needed to clarify causality and therapeutic implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13679-026-00713-8","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:47:35Z","timestamp":1776408455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Respiratory Disorders: A Systematic Review of Clinical and Pathophysiological Associations"],"prefix":"10.1007","volume":"15","author":[{"given":"Vasiliki Epameinondas","family":"Georgakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Steiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Androutsakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Karabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Reppas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"713_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"713_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"713_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. 2026;335:163\u201374. https:\/\/doi.org\/10.1001\/jama.2025.19615.","journal-title":"JAMA"},{"key":"713_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:20\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(22)00317-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"713_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-10086-8","author":"B Njei","year":"2025","unstructured":"Njei B, Boateng S, Mohamed M, Al-Ajlouni YA, Soliman M, Dranoff J, et al. Lean MASLD in U.S. adults: undiagnosed burden and metabolic features from NHANES 2017\u20132020. J Gen Intern Med. 2025. https:\/\/doi.org\/10.1007\/s11606-025-10086-8.","journal-title":"J Gen Intern Med"},{"key":"713_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/apt.18501","volume":"61","author":"D Kim","year":"2025","unstructured":"Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Loomba R, Ahmed A. Current burden of lean metabolic dysfunction-associated steatotic liver disease among US adults, 2017\u20132023. Aliment Pharmacol Ther. 2025;61:891\u20134. https:\/\/doi.org\/10.1111\/apt.18501.","journal-title":"Aliment Pharmacol Ther"},{"key":"713_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. Nafld and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691\u2013705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622.","journal-title":"Gut"},{"key":"713_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","volume":"46","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 2020;46:427\u201341. https:\/\/doi.org\/10.1016\/j.diabet.2019.12.007.","journal-title":"Diabetes Metab"},{"key":"713_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-025-00637-9","volume":"14","author":"C Koliaki","year":"2025","unstructured":"Koliaki C, Dalamaga M, Kakounis K, Liatis S. Metabolically healthy obesity and metabolic dysfunction-associated steatotic liver disease (MASLD): navigating the controversies in disease development and progression. Curr Obes Rep. 2025;14:46. https:\/\/doi.org\/10.1007\/s13679-025-00637-9.","journal-title":"Curr Obes Rep"},{"key":"713_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2025.05.013","volume":"83","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant P, Hubbard RA, Kaplan DE, Serper M. Cause-specific mortality in patients with steatotic liver disease in the United States. J Hepatol. 2025;83:860\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.013.","journal-title":"J Hepatol"},{"key":"713_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014.","journal-title":"Metabolism"},{"key":"713_CR12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","volume":"72","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2020.01.013.","journal-title":"J Hepatol"},{"key":"713_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/obr.12020","volume":"14","author":"G Musso","year":"2013","unstructured":"Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14:417\u201331. https:\/\/doi.org\/10.1111\/obr.12020.","journal-title":"Obes Rev"},{"key":"713_CR14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01923-2016","volume":"49","author":"D Viglino","year":"2017","unstructured":"Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski JP, et al. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017;49:1601923. https:\/\/doi.org\/10.1183\/13993003.01923-2016.","journal-title":"Eur Respir J"},{"key":"713_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34988-2","volume":"8","author":"D Viglino","year":"2018","unstructured":"Viglino D, Plazanet A, Bailly S, Benmerad M, Jullian-Desayes I, Tamisier R, et al. Impact of non-alcoholic fatty liver disease on long-term cardiovascular events and death in chronic obstructive pulmonary disease. Sci Rep. 2018;8:16559. https:\/\/doi.org\/10.1038\/s41598-018-34988-2.","journal-title":"Sci Rep"},{"key":"713_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262715","volume":"17","author":"JH Roh","year":"2022","unstructured":"Roh JH, Lee H, Yun-Jeong B, Park CS, Kim HJ, Yoon SY. A nationwide survey of the association between nonalcoholic fatty liver disease and the incidence of asthma in Korean adults. PLoS One. 2022;17:e0262715. https:\/\/doi.org\/10.1371\/journal.pone.0262715.","journal-title":"PLoS One"},{"key":"713_CR17","doi-asserted-by":"publisher","first-page":"13473","DOI":"10.1038\/s41598-021-92703-0","volume":"11","author":"GE Chung","year":"2021","unstructured":"Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Shin DW, Han K, Yu SJ. Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. Sci Rep. 2021;11:13473. https:\/\/doi.org\/10.1038\/s41598-021-92703-0.","journal-title":"Sci Rep"},{"key":"713_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-96710-3","volume":"15","author":"B Liu","year":"2025","unstructured":"Liu B, Jia Y, Gu Z, Li Y, Zhou Y, Cao Y. Metabolic dysfunction associated steatotic liver disease is associated with an increased risk of multiple respiratory system diseases. Sci Rep. 2025;15:15937. https:\/\/doi.org\/10.1038\/s41598-025-96710-3.","journal-title":"Sci Rep"},{"key":"713_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"713_CR20","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. accessed on March 2,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale (2026)."},{"key":"713_CR21","unstructured":"Joanna Briggs Institute. Checklist for analytical cross sectional studies. Critical appraisal tools for use in JBI systematic reviews [Internet]. Adelaide: Joanna Briggs Institute. 2017. Available from: https:\/\/jbi.global (accessed on March 2, 2026)."},{"key":"713_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61696-x","volume":"14","author":"D Zheng","year":"2024","unstructured":"Zheng D, Liu X, Zeng W, Zhou W, Zhou C. Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults. Sci Rep. 2024;14:10822. https:\/\/doi.org\/10.1038\/s41598-024-61696-x.","journal-title":"Sci Rep"},{"key":"713_CR23","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.2147\/COPD.S166902","volume":"13","author":"SW Moon","year":"2018","unstructured":"Moon SW, Kim SY, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Ro JS, Lee YH, Lee SH. Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007\u20132010. Int J Chron Obstruct Pulmon Dis. 2018;13:2603\u201311. https:\/\/doi.org\/10.2147\/COPD.S166902.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"713_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00887-w","volume":"14","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H, et al. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr. 2022;14:115. https:\/\/doi.org\/10.1186\/s13098-022-00887-w.","journal-title":"Diabetol Metab Syndr"},{"key":"713_CR25","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1111\/liv.14626","volume":"40","author":"HW Lee","year":"2020","unstructured":"Lee HW, Lee DH, Lee JK, Lee S, Koo BK, Joo SK, Heo EY, Jung YJ, Kim W, Kim DK. Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. Liver Int. 2020;40:3008\u201317. https:\/\/doi.org\/10.1111\/liv.14626.","journal-title":"Liver Int"},{"key":"713_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2025-003352","volume":"12","author":"CH Tseng","year":"2025","unstructured":"Tseng CH, Jou BY, Shen HC, Yeh HY, Hong SY, Lin YH, et al. Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction. BMJ Open Respir Res. 2025;12:e003352. https:\/\/doi.org\/10.1136\/bmjresp-2025-003352.","journal-title":"BMJ Open Respir Res"},{"key":"713_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2147\/IJGM.S339474","volume":"15","author":"F T\u00fcrker","year":"2022","unstructured":"T\u00fcrker F, Sah\u0131n T, Oral A, Ko\u00e7ak E, \u00c7avu\u015fo\u011flu T\u00fcrker B, Ni\u011fdelio\u011flu A, et al. Evaluation of predisposing metabolic risk factors for portopulmonary hypertension in patients with NASH cirrhosis. Int J Gen Med. 2022;15:859\u201365. https:\/\/doi.org\/10.2147\/IJGM.S339474.","journal-title":"Int J Gen Med"},{"key":"713_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/joim.13337","volume":"290","author":"MS J\u00f6rdens","year":"2021","unstructured":"J\u00f6rdens MS, Luedde M, Roderburg C, Demir M, Luedde T, Kostev K, et al. Pulmonary hypertension is associated with an increased incidence of NAFLD: a retrospective cohort study of 18,910 patients. J Intern Med. 2021;290:886\u201393. https:\/\/doi.org\/10.1111\/joim.13337.","journal-title":"J Intern Med"},{"key":"713_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1507\/endocrj.EJ24-0248","volume":"72","author":"T Sun","year":"2025","unstructured":"Sun T, Fan K, Han Z, Qiao H. Dose-response relationship between the fatty liver index and asthma risk: NHANES 2001\u2009~\u20092018. Endocr J. 2025;72:229\u201337. https:\/\/doi.org\/10.1507\/endocrj.EJ24-0248.","journal-title":"Endocr J"},{"key":"713_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03182-8","volume":"24","author":"T Feng","year":"2024","unstructured":"Feng T, Li J, Wu L, He X, Ye J. Association between metabolic dysfunction-associated steatotic liver disease and pulmonary function: a population-based and two-sample mendelian randomization study. BMC Pulm Med. 2024;24:368. https:\/\/doi.org\/10.1186\/s12890-024-03182-8.","journal-title":"BMC Pulm Med"},{"key":"713_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.sleep.2020.04.004","volume":"77","author":"I Jullian-Desayes","year":"2021","unstructured":"Jullian-Desayes I, Trzepizur W, Boursier J, Joyeux-Faure M, Bailly S, Benmerad M, et al. Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis. Sleep Med. 2021;77:357\u201364. https:\/\/doi.org\/10.1016\/j.sleep.2020.04.004.","journal-title":"Sleep Med"},{"key":"713_CR32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13623","volume":"13","author":"HA Jawa","year":"2021","unstructured":"Jawa HA, Khatib H, Alzahrani N, Alawi A, Al-Gamdi M, Abuljadayel A, et al. Nonalcoholic fatty liver disease and fibrosis risk in patients with obstructive sleep apnea: a retrospective analysis. Cureus. 2021;13:e13623. https:\/\/doi.org\/10.7759\/cureus.13623.","journal-title":"Cureus"},{"key":"713_CR33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/oby.21409","volume":"24","author":"P Benotti","year":"2016","unstructured":"Benotti P, Wood GC, Argyropoulos G, Pack A, Keenan BT, Gao X, Gerhard G, Still C. The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity. Obes (Silver Spring). 2016;24:871\u20137. https:\/\/doi.org\/10.1002\/oby.21409.","journal-title":"Obes (Silver Spring)"},{"key":"713_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf265","volume":"49","author":"W Trzepizur","year":"2026","unstructured":"Trzepizur W, Boursier J, Poilane J, Bureau C, Sedkaoui K, Pontier S, et al. Association between obstructive sleep apnea and liver fibrosis in patients with suspected nonalcoholic fatty liver disease. Sleep. 2026;49:zsaf265. https:\/\/doi.org\/10.1093\/sleep\/zsaf265.","journal-title":"Sleep"},{"key":"713_CR35","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2147\/NSS.S524675","volume":"17","author":"T Yu","year":"2025","unstructured":"Yu T, Zhou Y, Wu X, Fang Z, Liu C. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: epidemiological cross-sectional study and mendelian randomization analysis. Nat Sci Sleep. 2025;17:1361\u201376. https:\/\/doi.org\/10.2147\/NSS.S524675.","journal-title":"Nat Sci Sleep"},{"key":"713_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2025.104265","volume":"36","author":"C Beibei","year":"2026","unstructured":"Beibei C, Junhai Z, Zongbiao T, Fang P. Obstructive sleep apnea and metabolic-associated fatty liver disease risk: insights from National Health and Nutrition Examination Survey and Mendelian randomization analysis. Nutr Metab Cardiovasc Dis. 2026;36:104265. https:\/\/doi.org\/10.1016\/j.numecd.2025.104265.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"713_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1068756","volume":"14","author":"X Ding","year":"2023","unstructured":"Ding X, Zhao L, Cui X, Qi L, Chen Y. Mendelian randomization reveals no associations of genetically-predicted obstructive sleep apnea with the risk of type 2 diabetes, nonalcoholic fatty liver disease, and coronary heart disease. Front Psychiatry. 2023;14:1068756. https:\/\/doi.org\/10.3389\/fpsyt.2023.1068756.","journal-title":"Front Psychiatry"},{"key":"713_CR38","first-page":"176","volume":"32","author":"M Bocchino","year":"2015","unstructured":"Bocchino M, Brancaccio G, Rea G, De Martino M, Gaeta GB, Sanduzzi A. Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:176\u201380.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"713_CR39","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2026 report [Internet]. GOLD. 2026. Available from: goldcopd.org\/wp-content\/uploads\/2026\/01\/GOLD-REPORT-2026-v1.3-8Dec2025_WMV2.pdf (accessed on March 2, 2026)."},{"key":"713_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.diabet.2019.04.008","volume":"45","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Lonardo A, Vinco G, Zoppini G, Lippi G, Bonora E, et al. Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis. Diabetes Metab. 2019;45:536\u201344. https:\/\/doi.org\/10.1016\/j.diabet.2019.04.008.","journal-title":"Diabetes Metab"},{"key":"713_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038530","volume":"103","author":"HC Shen","year":"2024","unstructured":"Shen HC, Wang CH, Yang CW, Lin YH, Yeh HY, Perng DW, et al. Elevated neutrophil-to-lymphocyte ratio combined with decreased lymphocyte-to-monocyte ratio is associated with increased peripheral airway resistance in patients with hepatic steatosis. Medicine (Baltimore). 2024;103:e38530. https:\/\/doi.org\/10.1097\/MD.0000000000038530.","journal-title":"Medicine (Baltimore)"},{"key":"713_CR42","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1164\/rccm.201806-1109TR","volume":"199","author":"OA Mesarwi","year":"2019","unstructured":"Mesarwi OA, Loomba R, Malhotra A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease. Am J Respir Crit Care Med. 2019;199:830\u201341. https:\/\/doi.org\/10.1164\/rccm.201806-1109TR.","journal-title":"Am J Respir Crit Care Med"},{"key":"713_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151744","volume":"761","author":"J Kudo","year":"2025","unstructured":"Kudo J, Hirono H, Ohkoshi S. Low-frequency, mild-gradient chronic intermittent hypoxia still induces liver fibrogenesis in mice on a high-fat diet. Biochem Biophys Res Commun. 2025;761:151744. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151744.","journal-title":"Biochem Biophys Res Commun"},{"key":"713_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.bbrc.2017.06.047","volume":"490","author":"HH Kang","year":"2017","unstructured":"Kang HH, Kim IK, Lee HI, Joo H, Lim JU, Lee J, Lee SH, Moon HS. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4\/MyD88\/MAPK\/NF-kB signaling pathways. Biochem Biophys Res Commun. 2017;490:349\u201355. https:\/\/doi.org\/10.1016\/j.bbrc.2017.06.047.","journal-title":"Biochem Biophys Res Commun"},{"key":"713_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14116","volume":"54","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Li M, Ji G, Zhang L. Causal relationship between sleep apnea and non-alcoholic fatty liver disease: a Mendelian randomization study. Eur J Clin Invest. 2024;54:e14116. https:\/\/doi.org\/10.1111\/eci.14116.","journal-title":"Eur J Clin Invest"},{"key":"713_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77471-x","volume":"14","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Jiang C, Yin B, Wang H, Zong J, Yang T, et al. Investigating the causal links between obstructive sleep apnea and gastrointestinal diseases mediated by metabolic syndrome through mendelian randomization. Sci Rep. 2024;14:26247. https:\/\/doi.org\/10.1038\/s41598-024-77471-x.","journal-title":"Sci Rep"},{"key":"713_CR47","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77:1136\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.012.","journal-title":"J Hepatol"},{"key":"713_CR48","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1002\/cphy.c220020","volume":"13","author":"K Sun","year":"2023","unstructured":"Sun K, Li X, Scherer PE. Extracellular matrix (ECM) and fibrosis in adipose tissue: overview and perspectives. Compr Physiol. 2023;13:4387\u2013407. https:\/\/doi.org\/10.1002\/cphy.c220020.","journal-title":"Compr Physiol"},{"key":"713_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020169","volume":"10","author":"M Bantul\u00e0","year":"2021","unstructured":"Bantul\u00e0 M, Roca-Ferrer J, Arismendi E, Picado C. Asthma and obesity: two diseases on the rise and bridged by inflammation. J Clin Med. 2021;10:169. https:\/\/doi.org\/10.3390\/jcm10020169.","journal-title":"J Clin Med"},{"key":"713_CR50","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1073\/pnas.1621375114","volume":"114","author":"G Wernig","year":"2017","unstructured":"Wernig G, Chen SY, Cui L, Van Neste C, Tsai JM, Kambham N, et al. Unifying mechanism for different fibrotic diseases. Proc Natl Acad Sci U S A. 2017;114:4757\u201362. https:\/\/doi.org\/10.1073\/pnas.1621375114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"713_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler JHW, Gy\u00f6rfi AH, Ramanujam M, Whitfield ML, K\u00f6nigshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol. 2019;15:705\u201330. https:\/\/doi.org\/10.1038\/s41584-019-0322-7.","journal-title":"Nat Rev Rheumatol"},{"issue":"10309","key":"713_CR52","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(21)01961-9","volume":"398","author":"EA Renzoni","year":"2021","unstructured":"Renzoni EA, Poletti V, Mackintosh JA. Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia? Lancet. 2021;398(10309):1437\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(21)01961-9.","journal-title":"Lancet"},{"key":"713_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.794629","volume":"12","author":"J Geng","year":"2022","unstructured":"Geng J, Liu Y, Dai H, Wang C. Fatty Acid Metabolism and Idiopathic Pulmonary Fibrosis. Front Physiol. 2022;12:794629. https:\/\/doi.org\/10.3389\/fphys.2021.794629.","journal-title":"Front Physiol"},{"key":"713_CR54","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00109-023-02336-1","volume":"101","author":"R Chen","year":"2023","unstructured":"Chen R, Dai J. Lipid metabolism in idiopathic pulmonary fibrosis: from pathogenesis to therapy. J Mol Med (Berl). 2023;101:905\u201315. https:\/\/doi.org\/10.1007\/s00109-023-02336-1.","journal-title":"J Mol Med (Berl)"},{"key":"713_CR55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s13679-021-00434-0","volume":"10","author":"D Tsilingiris","year":"2021","unstructured":"Tsilingiris D, Tzeravini E, Koliaki C, Dalamaga M, Kokkinos A. The role of mitochondrial adaptation and metabolic flexibility in the pathophysiology of obesity and insulin resistance: an updated overview. Curr Obes Rep. 2021;10:191\u2013213. https:\/\/doi.org\/10.1007\/s13679-021-00434-0.","journal-title":"Curr Obes Rep"},{"key":"713_CR56","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: 2025 update. Available from: https:\/\/ginasthma.org\/wp-content\/uploads\/2025\/11\/GINA-2025-Update-25_11_08-WMS.pdf. (Accessed on March 12, 2026)."},{"key":"713_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13907","volume":"26","author":"MA Farhangi","year":"2025","unstructured":"Farhangi MA, Doumat G, Baroni IF, Camargo CA Jr. Weight loss and asthma control: a systematic review of randomized controlled trials. Obes Rev. 2025;26:e13907. https:\/\/doi.org\/10.1111\/obr.13907.","journal-title":"Obes Rev"},{"key":"713_CR58","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"key":"713_CR59","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/hep.26972","volume":"59","author":"P Martin","year":"2014","unstructured":"Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144\u201365. https:\/\/doi.org\/10.1002\/hep.26972.","journal-title":"Hepatology"},{"key":"713_CR60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/hep.27176","volume":"61","author":"M Thapar","year":"2015","unstructured":"Thapar M, Bonkovsky HL. Indications for liver transplant and AASLD guidelines. Hepatology. 2015;61:408. https:\/\/doi.org\/10.1002\/hep.27176.","journal-title":"Hepatology"},{"key":"713_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100410","volume":"28","author":"S Rozani","year":"2025","unstructured":"Rozani S, Dalamaga M, Weber G, Gr\u00fctzmann R. Liver transplantation in the era of obesity: a metabolic public health crisis meets a surgical frontier. Metab Open. 2025;28:100410. https:\/\/doi.org\/10.1016\/j.metop.2025.100410.","journal-title":"Metab Open"},{"key":"713_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100367","volume":"26","author":"VE Georgakopoulou","year":"2025","unstructured":"Georgakopoulou VE, Lazaridou A, Voulgaris A, Archontogeorgis K, Dalamaga M, Nena E, et al. Sleep quality and well-being in obesity-hypoventilation syndrome versus obstructive sleep apnea with obesity: a comparative study. Metab Open. 2025;26:100367. https:\/\/doi.org\/10.1016\/j.metop.2025.100367.","journal-title":"Metab Open"},{"key":"713_CR63","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2025.09.011","volume":"84","author":"L T\u00e9llez","year":"2026","unstructured":"T\u00e9llez L, Donate J, Guerrero A, Agulleiro Beraza I, San Mart\u00edn D, Alvarado E, et al. Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort. J Hepatol. 2026;84:284\u201392. https:\/\/doi.org\/10.1016\/j.jhep.2025.09.011.","journal-title":"J Hepatol"},{"key":"713_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2026.100449","volume":"29","author":"VE Georgakopoulou","year":"2026","unstructured":"Georgakopoulou VE, Dalamaga M. GLP-1 receptor agonists and obstructive lung disease: beyond metabolic control to respiratory outcomes. Metab Open. 2026;29:100449. https:\/\/doi.org\/10.1016\/j.metop.2026.100449.","journal-title":"Metab Open"},{"key":"713_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1649179","volume":"15","author":"F Chen","year":"2025","unstructured":"Chen F, Lyu L, Xing C, Chen Y, Hu S, Wang M, et al. The pivotal role of TGF-\u03b2\/Smad pathway in fibrosis pathogenesis and treatment. Front Oncol. 2025;15:1649179. https:\/\/doi.org\/10.3389\/fonc.2025.1649179.","journal-title":"Front Oncol"},{"key":"713_CR66","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"key":"713_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-025-00623-1","volume":"14","author":"I\u0391 Anastasiou","year":"2025","unstructured":"Anastasiou I\u0391, Argyrakopoulou G, Dalamaga M, Kokkinos A. Dual and triple gut peptide agonists on the horizon for the treatment of type 2 diabetes and obesity. An overview of preclinical and clinical data. Curr Obes Rep. 2025;14:34. https:\/\/doi.org\/10.1007\/s13679-025-00623-1.","journal-title":"Curr Obes Rep"},{"key":"713_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2022.100220","volume":"16","author":"IG Lempesis","year":"2022","unstructured":"Lempesis IG, Liu J, Dalamaga M. The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. Metab Open. 2022;16:100220. https:\/\/doi.org\/10.1016\/j.metop.2022.100220.","journal-title":"Metab Open"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00713-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00713-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00713-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:16:05Z","timestamp":1781648165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00713-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00713-8","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors of this article conducted any research using either human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and Human Rights and Informed Consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}